The past few years have seen remarkable progress in the HIV prevention field. Topical microbicides have had their first, modest demonstration of efficacy in women using tenofovir gel. Throughout the last six years the Microbicide Trials Network (MTN) has laid a foundation of additional studies to gird the clinical microbicide infrastructure. Over the next seven years, the MTN plans to expand the drugs and dosage forms brought into HIV prevention and we will focus our efforts on populations that are at high risk for HIV acquisition. As the Laboratory Center (LC) for the MTN we will provide laboratory oversight for the MTN scientific agenda to ensure compliance of all laboratories to good clinical laboratory practice. Additionally, the MTN LC will work with all NIH-sponsored HIV clinical trial networks and NIH contractors to harmonize laboratory methods and maximize the efficiency of protocol implementation. This will develop clear lines of communication between the MTN LC and associated Clinical Trials Units/Clinical Research Sites laboratories. Secondly, the MTN LC will work with the MTN Leadership Group and Statistical and Data Management Center to ensure the MTN scientific agenda continues to be responsive to protocol requirements for product safety and anticipated product efficacy. To accomplish our mission, the MTN LC will rely on three Core Laboratories: the Protocol Support Core led by Dr. Charlene Dezzutti along with Drs. Lisa Rohan, Sharon Hillier and lan McGowan who will provide their expertise for product testing, site support, sexually transmitted disease diagnoses, mucosal flora monitoring, mucosal immunity, and systems biology;the Virology Core led by Dr. John Mellors and Dr. Urvi Parikh who will provide the daily oversight for the HIV endpoint and drug resistance testing - primary endpoints for our protocols;and the Pharmacology Core led by Drs. Craig Hendrix and Peter Anderson who will provide their expertise for analyte analysis and assay development and define how much drug reaches the target tissue/cells and how long it remains - critical questions for topical microbicide development. Together, this remarkable team will strive to bring to licensure a safe and effective topical microbicide.

Public Health Relevance

Despite over 30 years into the HIV epidemic, modest advances have been to help people protect themselves from getting infected. The work done by the Microbicide Trials Network will bring forward new drugs and new ways to use them to prevent people from getting HIV. To do this, work will be done by a group of dedicated scientists to make sure safe and potent products are tested.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RRS-A (S1))
Program Officer
Black, Roberta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Magee-Women's Research Institute and Foundation
United States
Zip Code
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411
Justman, Jessica E; Nair, Gonasagrie Lulu; Hendrix, Craig W et al. (2018) Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. J Acquir Immune Defic Syndr 78:175-182
Mhlanga, Felix G; Noguchi, Lisa; Balkus, Jennifer E et al. (2018) Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. HIV Clin Trials 19:8-14
Balkus, Jennifer E; Brown, Elizabeth R; Palanee-Phillips, Thesla et al. (2018) Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. J Acquir Immune Defic Syndr 77:e8-e10
Musara, Petina; Montgomery, Elizabeth T; Mgodi, Nyaradzo M et al. (2018) How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe. AIDS Behav 22:877-886
Leu, Cheng-Shiun; Giguere, Rebecca; Bauermeister, José A et al. (2018) Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men. AIDS Care :1-9
Montgomery, Elizabeth T; Stadler, Jonathan; Naidoo, Sarita et al. (2018) Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results. AIDS 32:1517-1525
Makanani, Bonus; Balkus, Jennifer E; Jiao, Yuqing et al. (2018) Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy. J Acquir Immune Defic Syndr 79:566-572
Balán, Iván C; Giguere, Rebecca; Brown 3rd, William et al. (2018) Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. AIDS Behav 22:986-995
Giguere, Rebecca; Brown III, William; Balán, Ivan C et al. (2018) Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial? J Am Med Inform Assoc 25:393-400

Showing the most recent 10 out of 80 publications